ClinicalTrials.gg
WithdrawnNCT06235541Updated Jul 17, 2025

A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of GENA-104A16 in Advanced Solid Tumors, sponsored by Genome & Company. Withdrawn at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Genome & Company · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Study summary

This is a first in human phase I , open label study to evaluate the safety and tolerability of GENA 104A16 administered as a single agent by intravenous (IV) once every 2 weeks ( q2w (1 cycle = 2 weeks) in patients with advanced solid tumors, for who no standard therapy exists, or standard therapy has failed.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Genome & Company is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with histologically/ confirmed unresectable, recurrent, or advanced solid tumors
  • of at least 3 months
  • (ECOG) performance status (PS) score of 0 or 1
  • Adequate organ function including hematological, hepatic, and renal functions.
  • Negative
  • as per v1.1 defined as at least 1 lesion
  • Patients who are willing and able to comply with scheduled cycles, treatment plans, laboratory tests, and other procedures

Exclusion criteria

Exclusion Criteria:

  • A who has a positive urine pregnancy test prior to treatment
  • Received prior systemic anti-cancer therapy within 4 weeks or 5 half-life periods (whichever is shorter) prior to the first dose of treatment
  • Received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis
  • Received a live or within 30 days prior to the first dose of study intervention
  • Currently participating and receiving study treatments or has participated in a study of an agent and received the study therapy or has used an investigational device within 4 weeks prior to the first dose of study treatment
  • Had an allogeneic tissue/solid organ transplant
  • A diagnosis of immunodeficiency or is receiving chronic systemic therapy or any other form of therapy within 7 days prior the first dose of study drug
  • A known additional that is progressing or has required active treatment within the past 3 years
  • A known active and/or carcinomatous meningitis
  • A known prior severe reactions to monoclonal antibodies or any component in their formulation (Grade ≥3)
  • An active disease that has required systemic treatment in past 2 years
  • A history of (non infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • An active infection requiring systemic therapy, or has received a course of antibiotics within 4 weeks prior to the first dose of treatment
  • A known history of (HIV) infection
  • A known history of or known active virus (HCV) infection
  • Diagnosed with Gliosis through a brain MRI and has experienced neurological conditions within 6 months before the first administration
  • Has any one or more cardiovascular disease
  • A history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the patients participation for the full duration of the study
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    GENA104

    80 patients in total with histologically/cytologically confirmed unresectable, recurrent, or metastatic advanced solid tumors, for who no standard therapy exists, or standard therapy has failed will be enrolled in this study.

    Drug: GENA-104A16

Interventions

  • GENA-104A16 is administered as a 1 hour (h) \[-5 minutes and +60 minutes , i.e., 55-120 minutes as window time\] as intravenous (IV) infusion on q2w.

06

What researchers measure

Primary outcomes

  1. To determine the MTD and RP2D

    Incidence of dose limiting toxicity (DLT).

    Time frame: 1 year

  2. Incidence of Adverse Events

    Assessed as per CTCAE v5.0

    Time frame: 1 year

  3. Incidence of Laboratory abnormalities

    Assessed as per CTCAE v5.0

    Time frame: 1 year

Secondary outcomes

  1. Cmax for Pharmacokinetic (PK) profile

    Maximum serum concentration

    Time frame: 1 year

  2. Tmax for Pharmacokinetic (PK) profile

    Time to reach the maximum concentration

    Time frame: 1 year

  3. AUC0-tlast for Pharmacokinetic (PK) profile

    The area under the concentration-time curve from the time of dosing (time 0) to the time of the last observation

    Time frame: 1 year

  4. Half-life for Pharmacokinetic (PK) profile

    Measurement of half-life as PK parameter

    Time frame: 1 year

  5. Clearance for Pharmacokinetic (PK) profile

    Measurement of clearance as PK parameter

    Time frame: 1 year

  6. Potential immunogenicity

    Levels of human anti-GENA-104A16 antibody

    Time frame: 1 year

  7. Objective response rate (ORR)

    Assessed according to RECIST v1.1

    Time frame: 1 year

  8. Duration of response (DoR)

    Assessed according to RECIST v1.1

    Time frame: 1 year

  9. Progression free Survival (PFS)

    Assessed according to RECIST v1.1

    Time frame: 1 year

Other outcomes

  1. Tumor Biospecimens

    Levels of biomarkers expression with the observed antitumor activity

    Time frame: 1 year

  2. Blood Biospecimens

    Levels of biomarkers expression with the observed antitumor activity

    Time frame: 1 year

  3. Fecal Biospecimens

    Levels of biomarkers expression with the observed antitumor activity

    Time frame: 1 year

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Jongno-gu 03080, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2024; primary completion for Sep 2026, 31 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2024
First posted
Feb 1, 2024
StartEst.
Feb 2024
Primary completionEst.
Sep 2026
CompletionEst.
May 2027
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06235541
Lead sponsor
Genome & Company
Responsible party
Sponsor
First posted
Feb 1, 2024
Start date
Feb 2024 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Jul 17, 2025

Study contacts

Doyoun Oh
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CNTN4 Monoclonal Antibody GENA-104A16

Start the discussion